Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy
Publication
, Journal Article
El Chaer, F; McCloskey, J; Rein, LAM; Brown, RA; Green, SD; Pu, JJ; Shirane, S; Shimoda, K; Ichii, M; Yuda, J; Scandura, J; Kabir, S; Mei, J ...
Published in: Blood
November 15, 2022
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 15, 2022
Volume
140
Issue
Supplement 1
Start / End Page
594 / 595
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
El Chaer, F., McCloskey, J., Rein, L. A. M., Brown, R. A., Green, S. D., Pu, J. J., … Rampal, R. K. (2022). Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy. Blood, 140(Supplement 1), 594–595. https://doi.org/10.1182/blood-2022-159086
El Chaer, Firas, James McCloskey, Lindsay A. M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, et al. “Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy.” Blood 140, no. Supplement 1 (November 15, 2022): 594–95. https://doi.org/10.1182/blood-2022-159086.
El Chaer F, McCloskey J, Rein LAM, Brown RA, Green SD, Pu JJ, et al. Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy. Blood. 2022 Nov 15;140(Supplement 1):594–5.
El Chaer, Firas, et al. “Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, Nov. 2022, pp. 594–95. Crossref, doi:10.1182/blood-2022-159086.
El Chaer F, McCloskey J, Rein LAM, Brown RA, Green SD, Pu JJ, Shirane S, Shimoda K, Ichii M, Yuda J, Scandura J, Kabir S, Foulks JM, Mei J, Yang H, Wade M, Stapinski C, Lebedinsky C, Rampal RK. Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy. Blood. American Society of Hematology; 2022 Nov 15;140(Supplement 1):594–595.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 15, 2022
Volume
140
Issue
Supplement 1
Start / End Page
594 / 595
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology